- Home
- EARN vs IPHA Comparison
EARN vs IPHA Comparison
Compare EARN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- IPHA
- Stock Information
- Founded
- EARN 2012
- IPHA 1999
- Country
- EARN United States
- IPHA France
- Employees
- EARN N/A
- IPHA N/A
- Industry
- EARN Real Estate Investment Trusts
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- IPHA Health Care
- Exchange
- EARN Nasdaq
- IPHA Nasdaq
- Market Cap
- EARN 177.0M
- IPHA 191.0M
- IPO Year
- EARN 2013
- IPHA 2019
- Fundamental
- Price
- EARN $6.96
- IPHA $2.17
- Analyst Decision
- EARN Hold
- IPHA Strong Buy
- Analyst Count
- EARN 2
- IPHA 1
- Target Price
- EARN $6.00
- IPHA $11.50
- AVG Volume (30 Days)
- EARN 387.0K
- IPHA 6.3K
- Earning Date
- EARN 08-12-2024
- IPHA 09-12-2024
- Dividend Yield
- EARN 13.75%
- IPHA N/A
- EPS Growth
- EARN 102.38
- IPHA N/A
- EPS
- EARN 0.23
- IPHA N/A
- Revenue
- EARN $18,419,000.00
- IPHA $36,202,722.00
- Revenue This Year
- EARN N/A
- IPHA N/A
- Revenue Next Year
- EARN $51.24
- IPHA $105.84
- P/E Ratio
- EARN $30.08
- IPHA N/A
- Revenue Growth
- EARN N/A
- IPHA N/A
- 52 Week Low
- EARN $5.09
- IPHA $1.81
- 52 Week High
- EARN $7.26
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- EARN 54.17
- IPHA 49.44
- Support Level
- EARN $6.85
- IPHA $2.22
- Resistance Level
- EARN $6.95
- IPHA $2.41
- Average True Range (ATR)
- EARN 0.09
- IPHA 0.12
- MACD
- EARN 0.01
- IPHA -0.00
- Stochastic Oscillator
- EARN 65.62
- IPHA 47.06
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.